title: Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.
abstract: Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy.
  
  
  
  This commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management.
authors.affiliation: Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL. Electronic address: joseph.richard@mayo.edu.
authors.forename: Richard W
authors.initials: RW
authors.lastname: Joseph
authors.affiliation: Clinical Chief for Genitourinary Medicine, Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY.
authors.forename: Gurkamal
authors.initials: G
authors.lastname: Chatta
authors.affiliation: Professor of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI.
authors.forename: Ulka
authors.initials: U
authors.lastname: Vaishampayan
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D000077594:Nivolumab; D017410:Practice Guidelines as Topic
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab
keywords: Advanced renal cell carcinoma; Immune checkpoint inhibitor; Immunotherapy agents; Nivolumab; PD-1 inhibitor; Second-line therapy